

NEW VITEK®2 AST-GN CARDS

SUPPORTING ANTIMICROBIAL STEWARDSHIP



VITEK® 2 is a complete and integrated Antibiotic Susceptibility Testing (AST) solution designed to optimize laboratory efficiency, while helping to guide medical personnel to the correct choice for targeted antibiotic therapy.

Designed for the VITEK®2 automated system, the VITEK®2 AST-GN cards optimize the workflow of Gram-negative bacteria susceptibility testing by providing reliable and accurate results *

REFORMULATED
ANTIBIOTICS

NEW
ANTIBIOTICS

BROAD MIC
CALLING RANGE

AST-N437
(ref.424498)

Card that includes a large number of antibiotics for oral or systemic use with modes of administration compatible with the outpatient setting. ESBL confirmation test.

AST-N438
(ref. 424499)

Standard primary card, which includes reformulated Colistin.

AST-XN26
(ref. 424500)

Secondary card which contains the latest generation of antibiotics, including Meropenem/Vaborbactam and Imipenem/Relebactam, and ESBL confirmation test.
To be used in conjunction with the AST-N438 card.

AST-N439
(ref. 424501)

Card for multidrug-resistant bacteria, which contains the latest generation of antibiotics, including Meropenem/Vaborbactam, Imipenem/Relebactam and reformulated Colistin.

AST-N440
(ref. 424502)

Card for non-fermenting multidrug-resistant bacteria, which contains the latest generation of antibiotics, including Imipenem/Relebactam and reformulated Colistin.

AST-N438 – 424499

Antibiotic	MIC Range (mg/l)
Amikacin	1 - 64
Amoxicillin/Clav.acid (EUCAST)	4 - 64
Cefepime	0.12-32
Cefotaxime	0.25-64
Cefoxitin	4-64
Ceftazidime	0.12-64
Ciprofloxacin	0.06-4
Colistin NEW	0.125-8
Ertapenem	0.12-8
Fosfomycin	16-256
Gentamicin	1-16
Levofloxacin	0.12-8
Meropenem	0.25-16
Piperacillin/Tazobactam	4 - 128
Trimethoprim/Sulfa	20 - 320

AST-XN26 – 424500

Antibiotic	MIC Range (mg/l)
Ampicillin	2 - 32
Ampicillin/Sulbactam (EUCAST)	2 - 32
Aztreonam	1 - 64
Ceftazidime/Avibactam	0.12 - 16
Ceftolozane/Tazobactam	0.25 - 32
Ceftriaxone	0.25 - 64
Cefuroxime	1 - 64
Eravacycline	0.12 - 4
ESBL Confirm	+/-
Imipenem	0,25 - 16
Imipenem/Relabactam NEW	0,25 - 16
Meropenem/vaborbactam NEW	0,5 - 64
Moxifloxacin	0.25 - 8
Temocillin	4 - 32
Tigecycline	0.5 - 8
Tobramycin	1 - 16

AST-N439 – 424501

Antibiotic	MIC Range (mg/l)
Amikacin	1 - 64
Amoxicillin/Clav.acid	4 - 64
Cefepime	0.12 - 32
Ceftazidime	0.12 - 64
Ceftazidime/Avibactam	0.12 - 16
Ceftolozane/Tazobactam	0.25 - 32
Ciprofloxacin	0.06 - 4
Colistin NEW	0.125 - 8
Fosfomycin	16 - 256
Gentamicin	1 - 16
Imipenem/Relabactam NEW	0,25 - 16
Meropenem	0.25 - 16
Meropenem/vaborbactam NEW	0,5 - 64
Piperacillin/Tazobactam	4 - 128
Tigecycline	0.5 - 8

AST-N440 – 424502

Antibiotic	MIC Range (mg/l)
Amikacin	1 - 64
Ampicillin/Sulbactam (EUCAST)	2 - 32
Aztreonam	1 - 64
Cefepime	0.12 - 32
Ceftazidime	0.12 - 64
Ceftazidime/Avibactam	0.12 - 16
Ceftolozane/Tazobactam	0.25 - 32
Ciprofloxacin	0.06 - 4
Colistin NEW	0.125 - 8
Imipenem	0.25 - 16
Imipenem/Relabactam NEW	0,25 - 16
Meropenem	0.25 - 16
Piperacillin/Tazobactam	4 - 128
Tobramycin	1 - 16

AST-N437 – 424498

Antibiotic	MIC Range (mg/l)
Amikacin	1 - 64
Amoxicillin/Clav.acid	4 - 64
Ampicillin	2 - 32
Cefalexin	4 - 64
Cefixime	0.25 - 4
Cefpodoxime	0.25 - 8
Ceftazidime	0.12 - 64
Ceftriaxone	0.25 - 64
Ciprofloxacin	0.06 - 4
Ertapenem	0.12 - 8
ESBL Confirm	+/-
Fosfomycin	16-256
Gentamicin	1 - 16
Levofloxacin	0.12 - 8
Meropenem	0.25 - 16
Nitrofurantoin	16 - 512
Trimethoprim/Sulfa	20 - 320



*Bibliography

- E Riccobono, et al. Evaluation of VITEK® 2 AST cards (AST-N376 and AST-N397) for susceptibility testing of challenging Gram negatives. *Diagn Microbiol Infect Dis.* 2023.
- CG Carvalhaes, et al.. Performance of the Vitek 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in *Enterobacteriales* from North and Latin America. *Microbiol Spectr.* 2023.
- V Cortazzo, et al. Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of *Enterobacteriales* (*Enterobacteriaceae*) and *Pseudomonas aeruginosa* to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Assessed by In Vitro Testing Methods. *Antibiotics* (Basel). 2022.
- C Manuel, et al. Evaluation of Piperacillin-Tazobactam Testing against *Enterobacteriales* by the Phoenix, MicroScan, and Vitek2 Tests Using Updated Clinical and Laboratory Standards Institute Breakpoints. *J Clin Microbiol.* 2023.
- Dwivedi, et al. Multicenter clinical evaluation of VITEK 2® meropenem-vaborbactam for susceptibility testing of *Enterobacteriales* and *Pseudomonas aeruginosa*. *J Clin Microbiol* 2021.